Method for inducing extended self-renewal of functionally differentiated somatic cells

Patent metadata

Field	Value
Publication number	US-9175265-B2
Application number	US-201013382724-A
Country	US
Kind code	B2
Filing date	Jul 8, 2010
Priority date	Jul 8, 2009
Publication date	Nov 3, 2015
Grant date	Nov 3, 2015

Abstract

Mouse or human hematopoietic cells are transduced in vitro with one or more vectors encoding c-Myc and Klf4 genes, to overexpress both c-Myc and Klf4. The transduced cells produce self-renewing populations of macrophages, monocytes, monocyte-derived macrophages, B lymphocytes or erythroid cells. The self-renewing cell populations may include a pharmaceutical composition.

First claim

The invention claimed is:

1. A method for inducing extended self-renewal of mouse or human macrophages, B lymphocytes or erythroid cells comprising a step of activating overexpression of a c-Myc gene and a Klf4 gene in said cells by transducing said cells in vitro with a retroviral vector encoding c-Myc and said Klf4 gene.

2. The method according to claim 1 , wherein the retroviral vector is a lentiviral vector.

3. A population of mouse or human macrophages, B lymphocytes or erythroid cells in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf4 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf4 gene.

4. A pharmaceutical composition comprising a population of mouse or human macrophages, B lymphocytes or erythroid cells in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf4 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf4 gene;
and a pharmaceutically acceptable carrier or excipient.

5. A method for inducing extended self-renewal of mouse or human macrophages comprising a step of activating overexpression of a c-Myc gene and a Klf2 gene in said cells by transducing said cells in vitro with a retroviral vector encoding c-Myc and said Klf2 gene.

6. The method according to claim 5 , wherein the retroviral vector is a lentiviral vector.

7. A population of mouse or human macrophages in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf2 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf2 gene.

8. A pharmaceutical composition comprising a population of mouse or human macrophages in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf2 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf2 gene;
and a pharmaceutically acceptable carrier or excipient.

Assignees

• Sieweke Michael
• Inst Nat Sante Rech Med
• Centre Nat Rech Scient
• Univ Aix Marseille Ii

Inventors

• Sieweke Michael

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title